The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance: Real-world data of the C-PATROL study.
 
Frederik Marmé
Honoraria - AGENDIA; Amgen; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Eisai; Genomic Health; Gilead Sciences; GlaxoSmithKline; Immunomedics (Inst); Lilly; MSD Oncology; Myriad Genetics; Novartis; Pfizer; PharmaMar; Pierre Fabre; Roche/Genentech; Seagen
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); Clovis Oncology; CureVac; Eisai; Genomic Health; Gilead Sciences; GlaxoSmithKline; Immunomedics (Inst); Pfizer; Roche (Inst); Seagen; Seagen; Vaccibody (Inst)
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Tesaro (Inst); Vaccibody (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Pfizer; Roche
 
Felix Hilpert
Honoraria - AstraZeneca; GlaxoSmithKline; MSD; Novartis
Consulting or Advisory Role - AstraZeneca; MSD
 
Manfred Welslau
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Celgene; Gilead Sciences; Hexal; Janssen; Lilly; Novartis; Roche; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Gilead Sciences; Hexal; Janssen; Lilly; Medac; Novartis; Roche; Sanofi
 
Jacek P. Grabowski
Honoraria - AstraZeneca; Eisai; Esteve; GlaxoSmithKline; MSD
Consulting or Advisory Role - AstraZeneca; Eisai; Esteve; GlaxoSmithKline; MSD
Speakers' Bureau - AstraZeneca; Eisai; Esteve; GlaxoSmithKline; MSD
Research Funding - AstraZeneca (Inst); Esteve (Inst); GlaxoSmithKline (Inst); MSD (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Esteve; GlaxoSmithKline; MSD
 
Andreas Schneeweiss
Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Aurikamed; Bayer; Celgene; ClinSol; Connectmedica; Gilead Sciences; GlaxoSmithKline; I-MED; Lilly; MCI Deutschland; Metaplan; MSD; NanoString Technologies; Novartis; Onkowissen; Pfizer; Pierre Fabre; Promedicis; Roche; Seagen; Streamedup!; Tesaro; Teva; Thieme
Research Funding - Celgene (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Pfizer; Roche
 
Andreas D. Hartkopf
Honoraria - AstraZeneca; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Lilly; Menarini; MSD; Novartis; Onkowissen; Pfizer; RIEMSER; Roche; Seagen; Teva
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Menarini; MSD; Novartis; Onkowissen; Pfizer; RIEMSER; Roche; Teva
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Lilly; Menarini; Novartis; Pfizer; Roche
 
Dirk Bauerschlag
Honoraria - AstraZeneca; Eisai; MSD; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Eisai; MSD; Novartis
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; MSD; Novartis; Roche
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Roche
 
Christiane Brandi
No Relationships to Disclose
 
John-Kilian Rehbein
No Relationships to Disclose
 
Regina Glowik
Employment - AstraZeneca
 
Jalid Sehouli
Honoraria - AstraZeneca; Bayer; Clovis Oncology; Eisai; GlaxoSmithKline; Johnson & Johnson; MSD Oncology; Olympus Medical Systems; Pfizer; PharmaMar; Tesaro; Teva
Consulting or Advisory Role - Alkermes; AstraZeneca; Clovis Oncology; GlaxoSmithKline; Ingress Health; Johnson & Johnson; Lilly; Merck; MSD Oncology; Novartis; Novocure; Pfizer; PharmaMar; Riemser; Roche; Sobi; Tesaro
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG; Tesaro; Tesaro